TRAVERE THERAPEUTICS INC (TVTX) Stock Fundamental Analysis

NASDAQ:TVTX • US89422G1076

27.82 USD
-2.78 (-9.08%)
At close: Feb 13, 2026
28.01 USD
+0.19 (+0.68%)
After Hours: 2/13/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall TVTX gets a fundamental rating of 3 out of 10. We evaluated TVTX against 522 industry peers in the Biotechnology industry. TVTX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, TVTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • TVTX had negative earnings in the past year.
  • TVTX had a negative operating cash flow in the past year.
  • In the past 5 years TVTX always reported negative net income.
  • TVTX had a negative operating cash flow in each of the past 5 years.
TVTX Yearly Net Income VS EBIT VS OCF VS FCFTVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

  • TVTX's Return On Assets of -16.44% is fine compared to the rest of the industry. TVTX outperforms 78.35% of its industry peers.
  • TVTX has a Return On Equity (-120.36%) which is in line with its industry peers.
Industry RankSector Rank
ROA -16.44%
ROE -120.36%
ROIC N/A
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
TVTX Yearly ROA, ROE, ROICTVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • TVTX has a better Gross Margin (97.63%) than 97.32% of its industry peers.
  • TVTX's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for TVTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
TVTX Yearly Profit, Operating, Gross MarginsTVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • TVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TVTX has more shares outstanding
  • The number of shares outstanding for TVTX has been increased compared to 5 years ago.
  • The debt/assets ratio for TVTX is higher compared to a year ago.
TVTX Yearly Shares OutstandingTVTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TVTX Yearly Total Debt VS Total AssetsTVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • TVTX has an Altman-Z score of 0.16. This is a bad value and indicates that TVTX is not financially healthy and even has some risk of bankruptcy.
  • With a decent Altman-Z score value of 0.16, TVTX is doing good in the industry, outperforming 62.07% of the companies in the same industry.
  • TVTX has a Debt/Equity ratio of 4.23. This is a high value indicating a heavy dependency on external financing.
  • TVTX's Debt to Equity ratio of 4.23 is on the low side compared to the rest of the industry. TVTX is outperformed by 80.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.23
Debt/FCF N/A
Altman-Z 0.16
ROIC/WACCN/A
WACC8.1%
TVTX Yearly LT Debt VS Equity VS FCFTVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

2.3 Liquidity

  • TVTX has a Current Ratio of 2.75. This indicates that TVTX is financially healthy and has no problem in meeting its short term obligations.
  • TVTX's Current ratio of 2.75 is on the low side compared to the rest of the industry. TVTX is outperformed by 67.24% of its industry peers.
  • A Quick Ratio of 2.71 indicates that TVTX has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.71, TVTX is doing worse than 66.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.75
Quick Ratio 2.71
TVTX Yearly Current Assets VS Current LiabilitesTVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 75.91% over the past year.
  • Looking at the last year, TVTX shows a very strong growth in Revenue. The Revenue has grown by 114.22%.
  • The Revenue has been growing slightly by 5.87% on average over the past years.
EPS 1Y (TTM)75.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
Revenue 1Y (TTM)114.22%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%162.11%

3.2 Future

  • TVTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.71% yearly.
  • The Revenue is expected to grow by 41.73% on average over the next years. This is a very strong growth
EPS Next Y91.26%
EPS Next 2Y47.13%
EPS Next 3Y34.58%
EPS Next 5Y29.71%
Revenue Next Year118.08%
Revenue Next 2Y72.72%
Revenue Next 3Y55.73%
Revenue Next 5Y41.73%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TVTX Yearly Revenue VS EstimatesTVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
TVTX Yearly EPS VS EstimatesTVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TVTX. In the last year negative earnings were reported.
  • With a Price/Forward Earnings ratio of 41.18, TVTX can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of TVTX indicates a rather cheap valuation: TVTX is cheaper than 91.19% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.06. TVTX is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 41.18
TVTX Price Earnings VS Forward Price EarningsTVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVTX Per share dataTVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • TVTX's earnings are expected to grow with 34.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.13%
EPS Next 3Y34.58%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for TVTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TRAVERE THERAPEUTICS INC

NASDAQ:TVTX (2/13/2026, 8:00:01 PM)

After market: 28.01 +0.19 (+0.68%)

27.82

-2.78 (-9.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30
Earnings (Next)02-19
Inst Owners112.9%
Inst Owner Change-5.26%
Ins Owners0.79%
Ins Owner Change4.47%
Market Cap2.49B
Revenue(TTM)435.83M
Net Income(TTM)-88.54M
Analysts84.76
Price Target42.91 (54.24%)
Short Float %18.56%
Short Ratio6.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)143%
Min EPS beat(2)53.91%
Max EPS beat(2)232.09%
EPS beat(4)3
Avg EPS beat(4)68.35%
Min EPS beat(4)-27.29%
Max EPS beat(4)232.09%
EPS beat(8)4
Avg EPS beat(8)26.91%
EPS beat(12)6
Avg EPS beat(12)-40.48%
EPS beat(16)6
Avg EPS beat(16)-36.6%
Revenue beat(2)2
Avg Revenue beat(2)31.6%
Min Revenue beat(2)11.48%
Max Revenue beat(2)51.72%
Revenue beat(4)3
Avg Revenue beat(4)17.32%
Min Revenue beat(4)-0.02%
Max Revenue beat(4)51.72%
Revenue beat(8)6
Avg Revenue beat(8)9.84%
Revenue beat(12)9
Avg Revenue beat(12)2.67%
Revenue beat(16)9
Avg Revenue beat(16)-7.53%
PT rev (1m)1.38%
PT rev (3m)17.87%
EPS NQ rev (1m)65.34%
EPS NQ rev (3m)68.78%
EPS NY rev (1m)27.78%
EPS NY rev (3m)61.59%
Revenue NQ rev (1m)1.82%
Revenue NQ rev (3m)1.96%
Revenue NY rev (1m)0.56%
Revenue NY rev (3m)6.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 41.18
P/S 5.71
P/FCF N/A
P/OCF N/A
P/B 33.84
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.06
EYN/A
EPS(NY)0.68
Fwd EY2.43%
FCF(TTM)-1.2
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS4.87
BVpS0.82
TBVpS-0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.44%
ROE -120.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.63%
FCFM N/A
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
F-Score6
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 4.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 89.32%
Cap/Sales 11.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.75
Quick Ratio 2.71
Altman-Z 0.16
F-Score6
WACC8.1%
ROIC/WACCN/A
Cap/Depr(3y)142.8%
Cap/Depr(5y)123.81%
Cap/Sales(3y)28.66%
Cap/Sales(5y)21.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
EPS Next Y91.26%
EPS Next 2Y47.13%
EPS Next 3Y34.58%
EPS Next 5Y29.71%
Revenue 1Y (TTM)114.22%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%162.11%
Revenue Next Year118.08%
Revenue Next 2Y72.72%
Revenue Next 3Y55.73%
Revenue Next 5Y41.73%
EBIT growth 1Y67.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year106.01%
EBIT Next 3Y45.04%
EBIT Next 5Y34.35%
FCF growth 1Y64.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.81%
OCF growth 3YN/A
OCF growth 5YN/A

TRAVERE THERAPEUTICS INC / TVTX FAQ

What is the ChartMill fundamental rating of TRAVERE THERAPEUTICS INC (TVTX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to TVTX.


What is the valuation status for TVTX stock?

ChartMill assigns a valuation rating of 3 / 10 to TRAVERE THERAPEUTICS INC (TVTX). This can be considered as Overvalued.


How profitable is TRAVERE THERAPEUTICS INC (TVTX) stock?

TRAVERE THERAPEUTICS INC (TVTX) has a profitability rating of 2 / 10.